ASH Annual Meeting & Exposition: Lymphoma | Conference

KTE-X19 CAR T-Cell Therapy Effective for Relapsed/Refractory Mantle Cell Lymphoma
December 12, 2019

The ZUMA-II trial suggested that patients with relapsed/refractory mantle cell lymphoma resistant to prior therapies may benefit from the autologous anti-CD19 CAR T-cell therapy.

Matthew S. Davids, MD, MMSc, Discusses Study of Duvalisib in Combination with Venetoclax
December 10, 2019

Matthew S. Davids, MD, MMSc, discussed his phase I/II study of duvalisib combined with venetoclax for patients with relapsed/refractory CLL and SLL at the ASH Annual Meeting & Exposition.

Liso-Cel Shows Promise in Relapsed/Refractory Large B-Cell Lymphoma
December 09, 2019

Lisocabtagene maraleucel induced high response rates in patients with aggressive relapsed/refractory large B-cell lymphoma.

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
December 09, 2019

Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.

Combination Therapy Induces High Response Among Relapsed/Refractory Follicular Lymphoma
December 08, 2019

The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.

Off-The-Shelf Immunotherapy Product Induces Positive Response in Patients with NHL
December 07, 2019

Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.

Axi-Cel Improves OS in Patients with Refractory B-Cell Lymphoma
December 07, 2019

The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

Promising New Prognostic Score for High-Risk DLBCL
December 18, 2018

Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
December 06, 2018

The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

Can Venetoclax Plus R-CHOP Improve Outcomes in Aggressive DLBCL?
December 05, 2018

In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.